Dermatology News and Research

Latest Dermatology News and Research

Isotretinoin does not increase risk of inflammatory bowel disease

Doctors should not be discouraged from prescribing isotretinoin to adolescents for inflammatory acne, according to a new study by Canadian and U.S. scientists showing the drug does not increase the risk of inflammatory bowel disease (IBD).

22 Feb 2013

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) “auriclosene” (pronounced awr-rih-CLO-zeen) for the Company’s lead Aganocide® compound NVC-422.

21 Feb 2013

Sucampo launches RESCULA Eye Drops in the U.S.

Sucampo Pharmaceuticals, Inc. announced that RESCULA Eye Drops had been launched in the U.S. market.

21 Feb 2013

New bio-mimicking therapeutics could help treat skin wounds

In "before" and "after" photos from advertisements for wound-healing ointments, bandages and antibiotic creams, we see an injury transformed from an inflamed red gash to smooth and flawless skin. What we don't appreciate is the vital role that our own natural biomolecules play in the healing process, including their contribution to the growth of new cells and the development of new blood vessels that provide nutrients to those cells.

21 Feb 2013

Air pollution exposure raises cardiac death rate

Long-term exposure to high levels of particulate matter with a diameter of 2.5 mm or below increases a person’s chance for dying following a heart attack, show results from a large UK study.

20 Feb 2013

Symptom severity, hospice patient distress not necessarily linked

End-stage heart failure patients being treated in hospices have multiple symptoms with potential to cause distress, indicate US study findings.

20 Feb 2013

Liposomes not capable of transporting themselves deep into the skin

Liposomes are small fat capsules, often added to beauty products. According to the beauty industry liposomes are capable of transporting active ingredients deep into the skin and release the active ingredients so that they can alter the skin-s structure by rejuvenating and smoothing the skin.

20 Feb 2013

Medical nutrition therapy can play an important role in acne treatment

A study published in the Journal of the Academy of Nutrition and Dietetics has determined that there is increasing evidence of a connection between diet and acne, particularly from high glycemic load diets and dairy products, and that medical nutrition therapy (MNT) can play an important role in acne treatment.

20 Feb 2013

Income inequality equals more hospital readmissions

Patients living in areas of uneven wealth-distribution are at an increased risk for hospital readmission, according to US research findings published in the BMJ.

19 Feb 2013

High calcium intake raises all cause, CVD mortality risk for women

Latest research examining the potential hazards of a high calcium intake finds an increased mortality risk among women with a high intake through diet and supplements.

19 Feb 2013

Spherical nucleic acids could revolutionize biomedicine

Northwestern University's Chad A. Mirkin, a world-renowned leader in nanotechnology research and its application, has invented and developed a powerful material that could revolutionize biomedicine: spherical nucleic acids (SNAs).

16 Feb 2013

High diclofenac use questioned

Diclofenac remains one of the most widely recommended and regularly used non-steroidal anti-inflammatory drugs globally, despite its known association with increased cardiovascular risk, warn researchers who argue it should be removed from Essential Medicines Lists.

14 Feb 2013

Crowded emergency department has psychologic impact

The likelihood for patients with acute coronary syndromes developing post-traumatic stress disorder rises with emergency department crowding, research suggests.

14 Feb 2013

Regeneron fourth quarter total revenues increase to $415 million

Regeneron Pharmaceuticals, Inc. today announced financial and operating results for the fourth quarter and full year 2012 and provided an update on development programs.

14 Feb 2013

When a ‘nudge’ may be ethical for patient decision aids

There may be some scenarios in which patient decision aids should be designed to “nudge” patients toward a particular treatment option, according to a report by US researchers.

12 Feb 2013

Sucampo, R-Tech Ueno and Takeda file patent infringement lawsuit against Anchen for AMITIZA

Sucampo Pharmaceuticals, Inc. announced that it, together with R-Tech Ueno, Ltd., Sucampo AG, and Takeda Pharmaceutical Company Limited and certain affiliates of Takeda, has filed a patent infringement lawsuit against Anchen Pharmaceuticals, Inc., which had filed Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) to market a generic version of AMITIZA (lubiprostone) oral capsules, and certain affiliates of Anchen.

12 Feb 2013

Lipid associated variant linked to aortic stenosis, valve disorders

People who carry a lipoprotein(a) gene variant are at increased risk for aortic valve calcification and aortic stenosis, suggest study findings.

11 Feb 2013

Arrhythmia may confound heart failure treatment

Meta-analysis findings question whether beta-blocker treatment remains effective in patients who have heart failure with reduced left ventricular ejection fraction if they also have atrial fibrillation.

11 Feb 2013

Steroid therapy impedes Duchenne’s cardiomyopathy

Steroid therapy is associated with a considerable reduction in all-cause mortality and new-onset and progressive cardiomyopathy in patients with the debilitating X-linked disease Duchenne muscular dystrophy.

11 Feb 2013

Shire commences ABH001 Phase 3 study in Epidermolysis Bullosa

Shire plc, today announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a group of rare genetic skin disorders that begin to manifest at birth or early childhood and occur in approximately 19 per 1 million live births in the US.

10 Feb 2013